It would appear that our message on Cytodyn’s messaging has been received.
The announcement of trial continuation in cd12 s/c was appropriate. Highlighted that no concerns were raised and no trial modification requested.
(1)
(0)
CytoDyn Inc (CYDY) Stock Research Links
-
-
-
-
-
-
-